
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
BAJAJ BROKING
The GST Council has reduced GST rates on cancer drugs from 12% to 5%, making treatment more affordable. The reduction was part of the 54th GST Council meeting, where other tax changes included lower GST on snacks and higher rates on car seats.
In a significant decision aimed at reducing healthcare costs, the GST Council has reduced the Goods and Services Tax (GST) on cancer drugs from 12% to 5%. This reduction was finalised during the 54th GST Council meeting held in New Delhi, as part of broader efforts to make essential cancer treatment more affordable for patients across India.
The reduction of GST rates on cancer drugs is expected to ease the financial burden on thousands of cancer patients. The previous 12% tax on these life-saving drugs added to the already substantial treatment expenses faced by patients and their families. By bringing the tax down to 5%, the cost of cancer medication is expected to drop significantly, helping many afford the necessary treatments without straining their finances.
The GST Council has also made notable revisions in other sectors. The tax rate on selected snacks has been reduced from 18% to 12%, while the GST on car seats has been increased from 18% to 28%. Additionally, Roof Mounted Package Unit (RMPU) air conditioning machines for railways will now attract a GST rate of 28%, reflecting the government’s updated revenue policies.
The Council also introduced a new exemption, where funds granted for research purposes to universities established by Central and State laws, or those with income tax exemptions, will no longer be subjected to GST. This exemption is aimed at promoting more research activities across educational institutions in India, encouraging innovation and development.
Looking ahead, the GST Council has initiated steps to explore the possibility of reducing GST rates on life and health insurance. A Group of Ministers (GoM) has been set up to evaluate these proposals, with a final decision expected by November. This review signals potential relief for policyholders, further aligning GST policies with public welfare.
The latest GST rate revisions, especially the cut on cancer drugs, are set to have a substantial impact on citizens, easing healthcare costs while adjusting taxes across various sectors. The Council’s focus on supporting essential services and goods reflects a broader approach to tax rationalisation in India.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading